Phase I and pharmacologic study of oral ZD9331, a novel nonpolyglutamated thymidylate synthase inhibitor, in adult patients with solid tumors

Journal of Clinical Oncology

Volumn 20, Issue 7, 2002, Pages 1923-1931

  De Jonge, Maja J A ^a   Punt, Cornelis J A ^a   Sparreboom, Alex ^a   Planting, André S T ^a   Peters, M E W J ^a   Van de Schraaf, Jacqueline ^a   Jackman, Ann ^a   Smith, Rob ^a   De Mulder, Pieter H M ^a   Verweij, Jaap ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DEOXYURIDINE; PLEVITREXED; THYMIDYLATE SYNTHASE; THYMIDYLATE SYNTHASE INHIBITOR;

ADENOCARCINOMA; ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG RESPONSE; ENZYME INHIBITION; FEMALE; HUMAN; KIDNEY CARCINOMA; LIQUID CHROMATOGRAPHY; LUNG NON SMALL CELL CANCER; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SKIN TOXICITY; SOLID TUMOR; STOMACH CARCINOMA; TANDEM MASS SPECTROMETRY;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BONE MARROW; CHROMATOGRAPHY, LIQUID; DRUG ERUPTIONS; FEMALE; HUMANS; MALE; MASS SPECTROMETRY; MIDDLE AGED; NEOPLASMS; QUINAZOLINES; THYMIDYLATE SYNTHASE; TREATMENT OUTCOME;

EID: 0036534109     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.07.057     Document Type: Article

References (28)

1. The catalytic mechanism and structure of thymidylate synthase
2. Folate-based thymidylate synthase inhibitors as anticancer agents
3. Thymidylate synthase inhibitors
4. Antifolates in clinical development
5. Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines
6. Cellular pharmacokinetics of ZD1694 in cultured human leukemia cells sensitive, or made resistant, to this drug
7. The antitumour activity of ZD9331, a non-polyglutamatable quinazoline thymidylate synthase inhibitor
8. The influence of drug-exposure conditions on the development of resistance to methotrexate or ZD 1694 in cultured human leukemia cells
9. Molecular characterization of human acute leukemia cell line resistant to ZD9331, a non-polyglutamatable thymidylate synthase inhibitor
10. Molecular characterisation of two cell lines selected for resistance to the folate-based thymidylate synthase inhibitor, ZD1694
11. New folate analogues of the 10-deaza-aminopterin series: Basis for structural design and biochemical and pharmacologic properties
12. Obligate genetic expression in tumor cells of a fetal membrane property mediating "folate" transport: Biological significance and implications for improved therapy of human cancer
13. Cellular pharmacology and in vivo activity of a new anticancer agent, ZD9331: A water-soluble, non-polyglutamatable, quinazoline-based inhibitor of thymidylate synthase
14. ZD9331, a novel non-polyglutamated thymidylate synthase inhibitor: In vivo antitumour efficacy and toxicity to normal murine tissues
15. A phase I pharmacokinetic study of ZD9331, a novel long-acting thymidylate synthase inhibitor on a single dosing every 3 weeks schedule
16. Phase I study of ZD 9331 on short daily intravenous bolus infusion for 5 days every 3 weeks with fixed dosing recommendations
17. Phase I trial of ZD9331 in adult patients with refractory solid malignancies administered by 30-minute infusion on days 1 and 8 with the cycle repeated every 3 weeks
18. Phase I trial of ZD9331, a non-polyglutamatable thymidylate synthase inhibitor given as a 5-day continuous infusion every 3 weeks
19. The measurement of deoxynucleotide (dNTP) pools by radioimmunoassay (RIA)
20. The effect of ZD9331, a non-polyglutamated quinazoline thymidylate synthase inhibitor, on TTP and dUMP pools
21. Modified high- performance liquid chromatography assay for the measurement of 2'- deoxyuridine in human plasma and its application to pharmacodynamic studies of antimetabolite drugs
22. Plasma 2'deoxyuridine (dUrd) as a surrogate marker of thymidylate synthase (TS) inhibition in patients treated with ZD9331
23. Patient preferences for oral versus intravenous palliative chemotherapy
24. Preliminary studies of a novel oral fluoropyrimidine carbamate: Capecitabine
25. The tegafur-based dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines, UFT/leucovorin (ORZEL) and S-1: A review of their clinical development and therapeutic potential
26. Phase I trial of ZD9331, a non-polyglutamatable thymidylate synthase (TS) inhibitor given as a 5-day continuous infusion
27. 14C]-ZD9331 infused over 30 minutes in patients with advanced solid tumours
28. Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer